➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
McKinsey
Boehringer Ingelheim
McKesson
Dow

Last Updated: August 14, 2020

DrugPatentWatch Database Preview

Palivizumab - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for palivizumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
MedImmune LLCPhase 2/Phase 3
AbbViePhase 3
Regeneron PharmaceuticalsPhase 3

See all palivizumab clinical trials

Recent Litigation for palivizumab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Reckitt Benckiser Pharmaceuticals Inc. v. Watson Laboratories Inc.2013-10-08
PIECZENIK v. BAYER CORPORATION2010-05-04

See all palivizumab litigation

PTAB Litigation
PetitionerDate
2017-12-20

See all palivizumab litigation

Pharmacology for palivizumab
Ingredient-typeAntibodies, Monoclonal
Mechanism of ActionFusion Protein Inhibitors

Patent Text Search: US Patents for palivizumab

These patents were identified by searching patent claims

Supplementary Protection Certificates for palivizumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
138 Luxembourg   Start Trial PRODUCT NAME: RITUXIMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20140326
2015 00043 Denmark   Start Trial PRODUCT NAME: TRASTUZUMAB OG REKOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: C(20135603) /EU/1/00/145/002 20130826
2016000049 Germany   Start Trial PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
780 Luxembourg   Start Trial PRODUCT NAME: TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20130826
0822 Netherlands   Start Trial PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326
2016000070123 Italy   Start Trial PRODUCT NAME: RITUXIMAB IN ASSOCIAZIONE CON IALURONIDASI RICOMBINANTE UMANA - SOLUZIONE PER INIEZIONE SOTTOCUTANEA(MABTHERA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/98/067/001-003, 20140326
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
AstraZeneca
Mallinckrodt
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.